Oppenheimer Maintains a Hold Rating on Agios Pharma (AGIO)

By Ryan Adsit

Oppenheimer analyst Leah R. Cann maintained a Hold rating on Agios Pharma (AGIOResearch Report) today. The company’s shares opened today at $66.83.

Cann said:

“The updated data for AG-881 ongoing phase I study presented today include approximately three months of additional data from time of last presentation. The data continue to show a favorable safety profile with no new DLTs since the last presentation. Tumor volume growth in the non-enhancing patients is very encouraging, compared to patients in the natural history study, 6.8% and 24.5%, respectively. We believe AG-881 is a promising early-stage molecule. We have not included any impact from AG-881 in our outlook through 2022, but data presented today at SNO are highly encouraging in gliomas, especially the non-enhancing patients.”

According to TipRanks.com, Cann is a 3-star analyst with an average return of 1.6% and a 38.9% success rate. Cann covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, Miragen Therapeutics Inc, and CytomX Therapeutics Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Agios Pharma with a $83.67 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $99.82 and a one-year low of $51.62. Currently, Agios Pharma has an average volume of 433.4K.

Based on the recent corporate insider activity of 62 insiders, corporate insider sentiment is neutral on the stock. Most recently, in September 2018, David Schenkein, the CEO of AGIO bought 8,730 shares for a total of $276,217.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.